MONDAY, MARCH 22
Welcoming Remarks and Keynote Session (Joint) (8am Denver/Mountain Time Start)

*Jay D. Horton, University of Texas Southwestern Medical Center, USA
*Alphonse E. Sirica, Virginia Commonwealth University, USA
Helen H. Hobbs, University of Texas Southwestern Medical Center, USA

PNPLA3's Role in NAFLD
Hashem B. El-Serag, Baylor College of Medicine, USA

Changing Epidemiological Trends in Non-Alcoholic Fatty Liver Disease versus Viral-Associated Hepatobiliary Cancers

Non-Alcoholic Fatty Liver Disease, Liver Inflammation and Fibrogenesis in the Pathogenesis of Hepatobiliary Cancers (Joint) (9:10am Denver/Mountain Time Start)

*Jay D. Horton, University of Texas Southwestern Medical Center, USA
*Alphonse E. Sirica, Virginia Commonwealth University, USA
Lopa Mishra, George Washington University, USA

TGF-beta Signaling in Liver Fibrosis and Hepatocellular Carcinoma
Maria Rescigno, Humanitas University, Italy

The Gut-Liver Axis in Liver Cancer Risk Conditions
Daniel A. Heller, Memorial Sloan Kettering Cancer Center, USA

Lipid Dysregulation in Inflammation, NASH, and Cancer

Tumor Microenvironment and Hepatobiliary Cancers (3pm Denver/Mountain Time Start) (EK29)

*Lopa Mishra, George Washington University, USA
Silvia Affo, Columbia University, USA

Role of Cancer Associated Fibroblasts in Cholangiocarcinoma

Amaia Lujambio, Icahn School of Medicine at Mount Sinai, USA

Mechanisms of Immune Escape in Hepatocellular Carcinoma

Alphonse E. Sirica, Virginia Commonwealth University, USA

The Desmoplastic Reaction and Intrahepatic Cholangiocarcinoma Progression: CAFs, Select Molecular Drivers, and Prognostic Implications

*Gregory J. Gores, Mayo Clinic, USA

Targeting the Tumor Microenvironment for Cholangiocarcinoma Therapy

Genetics of NAFLD (3pm Denver/Mountain Time Start) (EK28)

Elizabeth K. Speliotes, University of Michigan, USA

Use of GWAS to Identify SNPs Associated with NAFLD

Noura S. Abul-Husn, Icahn School of Medicine at Mount Sinai, USA

Genomics and Liver Disease in Diverse Populations: From Biobanks to Patients

NAFLD and CVD (4:30pm Denver/Mountain Time Start) (EK28)

Henry N. Ginsberg, Columbia University College of Physicians and Surgeons, USA

The AAA ATPase Torsin A, a New, Potent Player in VLDL Secretion, NAFL, and NASH

Jay D. Horton, University of Texas Southwestern Medical Center, USA

Molecular Mediators of NAFLD and Hyperlipidemia

TUESDAY, MARCH 23
Hepatobiliary Cancer Biomarkers and Molecular Subtypes (8am Denver/Mountain Time Start) (EK29)

*Gregory J. Gores, Mayo Clinic, USA
*Alphonse E. Sirica, Virginia Commonwealth University, USA
Yujin Hoshida, UT Southwestern Medical Center, USA

Liver Cancer Risk-Predictive Molecular Biomarkers Specific to Clinico-Epidemiological Contexts

Augusto Villanueva Rodriguez, Icahn School of Medicine at Mount Sinai, USA

Liquid Biopsy in Hepatobiliary Cancers

Jessica Zucman-Rossi, University Paris Descartes-HEGP, France

Mechanisms of Liver Carcinogenesis Define Specific Molecular and Phenotypic HCC Subgroups

Jesper Beje Andersen, University of Copenhagen, Denmark

Defining Distinct Subtypes of Intrahepatic Cholangiocarcinoma by Molecular Profiling: Diagnostic, Prognostic, and Therapeutic Applications

Robert F. Schwabe, Columbia University, USA

Discovery of Subgroup-Specific HCC Master Regulators by Systems Biology Approaches

Role of Lipids in NAFLD (8am Denver/Mountain Time Start) (EK28)

Mitchell A. Lazar, Perelman School of Medicine, University of Pennsylvania, USA

Circadian Contributions to NAFLD

Catherine Pottic, INSERM Institut Cochin, France

Altered Insulin Signaling and Glucose Toxicity in NAFLD

Hannele Yki-Järvinen, University of Helsinki, Finland

Effects of Genetic Risk Factors for NAFLD on Hepatic Lipid Metabolism

Eran Elinav, Weizmann Institute of Science, Israel

Host Microbiome Interactions in Health and Disease

* Session Chair † Invited but not yet accepted  Program current as of February 26, 2021.
For the most up-to-date details, visit https://www.keystonesymposia.org.
Meet the Editors (Joint) (12:30pm Denver/Mountain Time Start)
Genomics, Molecular Heterogeneity, and Precision Medicine in Hepatobiliary Cancers (3pm Denver/Mountain Time Start) (EK29)
* Lopa Mishra, George Washington University, USA
* Alphonse E. Sirica, Virginia Commonwealth University, USA
Irene Oi Lin Ng, University of Hong Kong, Hong Kong
Molecular Biomarkers in Hepatocellular Carcinoma

Xin Wei Wang, NCI, National Institutes of Health, USA
Causes and Functional Intricacies of Intertumor and Intratumor Heterogeneity in Primary Hepatobiliary Cancers

Renumathy Dhanasekaran, Stanford University, USA
Complexities of Genetic Heterogeneity in Hepatocellular Carcinoma

Bin Tean Teh, Duke-NUS Medical School, Singapore
Genomic and Epigenomic Studies of Cholangiocarcinoma and their Clinical Implications

Josep Llovet, Icahn School of Medicine at Mount Sinai, USA
Immune Therapies for HCC: is NASH-HCC Responding Different

Pathways to NASH (3pm Denver/Mountain Time Start) (EK28)
Mark A. McNiven, Mayo Clinic, USA
Lipid Droplet Formation and Lipophagy in Fatty Liver Disease

Tobias C. Walther, Harvard School of Public Health, USA
Lipid Droplet Biology in NAFLD

Emerging Therapies for NASH-I (4:30pm Denver/Mountain Time Start) (EK28)
Chuhan Chung, Gilead Sciences, USA
Combination Therapies for NASH Cirrhosis

WEDNESDAY, MARCH 24

Advances in Molecular and Immune Targeting of Hepatobiliary Cancers (8am Denver/Mountain Time Start) (EK29)
* Gregory J. Gores, Mayo Clinic, USA
* Lopa Mishra, George Washington University, USA
Tim F. Greten, NCI, National Institutes of Health, USA
Immunotherapies for Hepatobiliary Cancers: Current Status and Future Perspectives

R. Kate Kelley, University of California, San Francisco, USA
Developing Clinical Trials of Novel Therapeutic Agents and Treatment Combinations for Intrahepatic Cholangiocarcinoma

Bruno Sangro, Clinica Universidad de Navarra, Spain
Targeted Agent and Immune-Based Therapies for Hepatocellular Carcinoma

Emerging Therapies for NASH-II (8am Denver/Mountain Time Start) (EK28)

Morris J. Birnbaum, Pfizer Inc., USA
DGAT2 Inhibition for NASH

Greg Steinberg, McMaster University, Canada
Role of ATP Citrate Lyase (ACLY) in NASH and HCC

Kendra K. Bence, Pfizer Inc., USA
Inhibition of Fructose Metabolism for the Treatment of NAFLD

Lei Ling, NGM Biopharmaceuticals, USA
Therapeutic FGF19 in Non-Alcoholic Steatohepatitis

Closing Remarks (10:50am Denver/Mountain Time Start) (EK29)
Closing Remarks (10:50am Denver/Mountain Time Start) (EK28)